Alexion Pharmaceuticals Inc ALXN:NASDAQ

Last Price$110.85NASDAQ Previous Close - Last Trade as of 3:59PM ET 8/16/19

Today's Change+1.81(1.66%)
Bid (Size)$110.79 (1)
Ask (Size)$114.71 (1)
Day Low / High$109.57 - 111.41
Volume1.3 M
 

View Biotechnology IndustryPeer Comparison as of 08/16/2019

 

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $110.85
Change: +1.81 (1.66%)
Volume: 1.3 M
3:59PM ET 8/16/2019
 
 

Agilent Technologies Inc ( NYSE )

Price: $71.11
Change: +0.03 (0.04%)
Volume: 3.4 M
4:00PM ET 8/16/2019
 
 

Incyte Corp ( NASDAQ )

Price: $83.12
Change: +2.51 (3.11%)
Volume: 1.1 M
3:59PM ET 8/16/2019
 
 

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $296.85
Change: +3.74 (1.28%)
Volume: 742.6 K
4:00PM ET 8/16/2019
 
 

Exact Sciences Corp ( NASDAQ )

Price: $119.82
Change: +1.60 (1.35%)
Volume: 918.1 K
4:00PM ET 8/16/2019
 

Read more news Recent News

--Analyst Actions: JPMorgan Starts Alexion Pharmaceuticals at Overweight, Lowers PT to $172 From $179
10:59AM ET 7/31/2019 MT Newswires

Price: 115.11, Change: +0.66, Percent Change: +0.58 ...

Q3, 2019, and 2020 Earnings Estimates for Alexion Pharmaceuticals Increased
11:36PM ET 7/29/2019 MT Newswires

Q3, 2019, and 2020`s earnings projections for Alexion Pharmaceuticals Inc (NASDAQ:ALXN, Recent Price: 112.36) have been scaled up. The Q3 earnings estimate...

Alexion Pharmaceuticals Gets Positive Opinion from European Agency for Treatment of Neuro Disorder
3:24PM ET 7/26/2019 MT Newswires

Alexion Pharmaceuticals (ALXN) said Friday that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a...

Alexion Pharmaceuticals' Q3, 2019 and 2020 Earnings Estimates Raised
11:26PM ET 7/25/2019 MT Newswires

Q3, 2019, and 2020`s forecasted earnings estimates for Alexion Pharmaceuticals Inc (NASDAQ:ALXN, Recent Price: 118.03) have been revised upward. The Q3...

Company Profile

Business DescriptionAlexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. View company web site for more details
Address121 Seaport Boulevard
Boston, Massachusetts 02210
Phone+1.475.230.2596
Number of Employees2,656
Recent SEC Filing07/24/20198-K
Chief Executive Officer & DirectorLudwig N. Hantson
Chief Financial Officer & Executive Vice PresidentPaul J. Clancy
Executive VP, Head-Research & DevelopmentJohn J. Orloff
Chief Compliance Officer & Executive VPIndrani M. Franchini

Company Highlights

Price Open$110.27
Previous Close$109.04
52 Week Range$92.56 - 141.86
Market Capitalization$24.9 B
Shares Outstanding224.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement10/23/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings18.72
Earnings per Share$7.31
Beta vs. S&P 500N/A
Revenue$4.1 B
Net Profit Margin29.84%
Return on Equity13.96%

Analyst Ratings as of 08/09/2019

Buy
13
Overweight
3
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset